Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. by Worni-Schudel, Inge et al.
Preventive Medicine Reports 24 (2021) 101583
Available online 7 October 2021
2211-3355/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Association between self-reported motivation to quit smoking with 
effectiveness of smoking cessation intervention among patients hospitalized 
for acute coronary syndromes in Switzerland 
Inge Worni-Schudel a, Vasilis Tzalis a, Julian Jakob a,b, Kali Tal a, Lauriane Gilgien-Dénéréaz c, 
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A B S T R A C T   
Guidelines recommend brief smoking cessation interventions for hospitalized smokers reporting low motivation- 
to-quit. However, an intensive smoking cessation intervention may improve smoking cessation for these smokers. 
We conducted a secondary analysis of a pre-post interventional study that tested the efficacy of a proactive 
approach systematically offering intensive smoking cessation intervention to all hospitalized smokers with acute 
coronary syndrome (ACS) compared to a reactive approach offering it only to smokers willing to quit. 
We analyzed data from one study site in Switzerland, which recorded motivation-to-quit smoking at study 
inclusion between 08.2009 and 02.2012. The primary outcome was smoking cessation at 1- and 5-year. We 
tested for interaction by participant’s motivation-to-quit score (low vs. high motivation), and calculated 
multivariable adjusted risk ratios (RR), stratified by motivation score. 
We obtained motivation scores for 230 smokers. Follow-up was 94% (217/230) at 1-year and 68% (156/230) 
at 5-year. Among participants with low motivation to quit, 19% of smokers in the reactive phase had quit at 1 
year compared to 50% of smokers in the proactive phase (multivariable adjusted RR = 2.85, 95%CI:0.91–8.91). 
Among highly motivated smokers, rates did not differ between phases: 48% vs. 49% (multivariable adjusted RR 
= 1.02, 95%CI:0.75–1.39, p-value for interaction between motivation-to-quit categories = 0.10). At 5-year 
follow-up, the point estimates were similar. 
While our study has limitations inherent to the study design and sample size, we found that a proactive 
approach to offer systematic smoking cessation counseling for smokers with ACS reporting low motivation to quit 
was associated with higher smoking cessation rates at 1 year.   
1. Introduction 
Effective smoking cessation counseling is an essential component of 
secondary preventive care after acute coronary syndromes (ACS). 
Guidelines recommend that healthcare providers ask patients if they 
smoke, assess their readiness to quit, assist smokers willing to quit with 
counseling, and arrange a follow-up contact (the “5A’s”) (Fiore et al., 
2012), but recommend only minimal intervention if smokers are not 
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ready to quit. Recommended smoking cessation interventions are usu-
ally reactive, offered as an ‘opt-in’ approach (Richter and Ellerbeck, 
2015), but the effectiveness of the opt-in approach has been recently 
challenged (Aveyard et al., 2012; Richter and Ellerbeck, 2015). Some 
have questioned the opt-in approach because it does not align with the 
proactive approach of interventions to treat other cardiovascular risk 
factors such as diabetes, dyslipidaemia and hypertension (Richter and 
Ellerbeck, 2015). In these interventions, treatment is offered systemat-
ically and patients can refuse (opt-out) (Faseru et al., 2017). An opt-out 
approach to smoking cessation would offer counseling to all smokers, 
whether or not they are ready to quit. 
There is evidence suggesting that opt-out interventions for smoking 
cessation counseling are more effective than opt-in interventions for 
smokers in the outpatient setting (Aveyard et al., 2012; Fu et al., 2016; 
Fu et al., 2014; Japuntich et al., 2020; Pisinger et al., 2005b; Richter and 
Ellerbeck, 2015), but there is less evidence for its efficacy among hos-
pitalized smokers (Faseru et al., 2017). We already conducted a pre-post 
interventional study that tested the acceptance and efficacy of a pro-
active, opt-out intervention based on motivational interviewing (MI), a 
non-judgmental, patient-centered counseling approach, with promising 
results (Auer et al., 2016). MI guides smokers through the process of 
behaviour change rather than solely offering smokers advice and rec-
ommendations based on their stated motivation (Codern-Bové et al., 
2014; Lindson-Hawley et al., 2015, 2011; Miller and Rollnick, 2012). 
In our study, we systematically offered MI-based intensive smoking 
cessation intervention to all smokers hospitalized for ACS in the pro-
active, opt-out, phase and compared it to a reactive, opt-in, phase where 
we only offered smokers a smoking cessation intervention when their 
healthcare provider requested one (Auer et al., 2016). The proactive 
approach yielded promising smoking cessation outcomes, but the dif-
ferences between phases were not statistically significant. One of our 
four study sites recorded motivation to quit at study inclusion during the 
proactive and the reactive phases of the study. Thus, we tested the hy-
pothesis whether a proactive approach of systematically offering 
smoking cessation intervention to all smokers, regardless of self- 
reported motivation-to-quit, benefited smokers who state they are not 
motivated-to-quit more than a reactive approach. 
We set out to determine whether a higher proportion of smokers with 
low motivation-to-quit received an intensive MI-based smoking cessa-
tion intervention and quit smoking at 1- and 5-years follow-up when 
they were included during the proactive phase than those included 
during the reactive phase. 
2. Materials and methods 
We report data from participants enrolled in the study site of Lau-
sanne, Switzerland; one of the four study sites of the Special Program 
University Medicine-Acute Coronary Syndrome (SPUM-ACS) prospec-
tive cohort study (NTC 01000701, clinicaltrials.gov). 
We defined current smoking as smoking one cigarette or more per 
day during the month before hospitalization. Participants were included 
consecutively in the reactive phase (08/2009 to 10/2010) or in the 
proactive phase (11/2010 to 02/2012). In the proactive phase, a resi-
dent physician trained in MI systematically approached all included 
smokers and asked permission to discuss their smoking habits (Auer 
et al., 2016). In the reactive phase, clinicians in charge could request 
dedicated smoking cessation counseling based on their assessment of a 
patient’s needs. 
At study entry, before any dedicated smoking cessation intervention, 
study nurses asked all participants: “On a scale from 1 (not motivated at 
all) to 10 (maximal motivation), what is your motivation to stop smoking?” 
Our primary outcome was self-reported 7-day smoking abstinence at the 
in-person 1-year follow-up and 5-years phone follow-up, assessed by a 
single question. Smoking abstinence was validated by expired CO level 
at 1-year follow-up. Carbon monoxide levels of 10 ppm or were identi-
fying participants as current smokers. Secondary outcomes were 
delivery of smoking cessation intervention, time spent in counseling, 
and prescription of nicotine replacement therapy (NRT) at discharge. 
We computed risk ratios (RR) with 95% confidence intervals (CI) for 
smoking cessation outcomes at 1- and 5-year follow-up. To determine 
whether the initial motivation to quit smoking modified the effect of the 
intervention, we tested for interaction by dichotomous motivation score 
on smoking cessation rates at 1 year. Due to limited sample size, we used 
the alpha level of 0.10 to determine significant interaction. We stratified 
analyses on smoking cessation outcomes by participants’ self-reported 
motivation-to-quit score at baseline (low motivation [1–5] and high 
motivation [6–10]. The cut-off for low vs high motivation was decided 
based on clinical judgment and arbitrarily set at the mean of the visual 
analog scale (1–5 and 6–10). Since we did not plan these analyses when 
we set up the trial, and therefore did not register our hypothesis or the 
cut-offs in a repository beforehand, cut-off should be considered a post- 
hoc decision and results considered exploratory. 
We fitted multivariable adjusted generalized linear models following 
a negative binomial distribution, adjusted for demographic (age, sex, 
education), baseline smoking intensity (cigarettes per day), and for type 
of ACS. We excluded participants lost to follow-up from main analyses 
but performed sensitivity analysis including them as continuous 
smokers. Analyses were performed using STATA 17.0 (StataCorp, Texas, 
USA). 
3. Results 
Between August 2009 and February 2012, 616 participants admitted 
for ACS were included in the study; of these, 245 were smokers (Auer 
et al., 2016). We obtained motivation scores at baseline for 230 par-
ticipants. At one year, 217/230 (94%) of these participants were 
available for follow-up; 8 (3.5%) had died, 5 (2%) were lost to follow-up. 
At 5 years, 156/230 (68%) were available for follow-up; 23 (10%) had 
died, 47 (20) were lost to follow-up (see flow diagram in online Ap-
pendix). Median age was 55 years; 22% were women. Sex, education, 
and cigarettes smoked per day were equally distributed across categories 
(Table 1). People were younger in the high motivation group than in the 
low motivation group (p = 0.014). 
Among those with low motivation, 14% (N = 4) participants received 
a smoking cessation counseling intervention in the reactive phase and 
78% (N = 14) in the proactive phase. NRT prescriptions increased more 
in those with low motivation than in those with high motivation to quit 
between reactive and proactive phases (Table 2). The median duration 
of counseling was 45 min in reactive phase and 50 in the proactive phase 
and did not differ by motivation-to-quit categories (Table 2). We found a 
significant interaction between motivation-to-quit score and study 
phases on smoking cessation at 1 year (p for interaction = 0.10). In 
stratified analyses by motivation to-quit-score, we found that 1-year 
smoking cessation rates were 19% in the reactive phase compared to 
50% in the proactive phase among participants with low motivation-to- 
quit at baseline, multivariable adjusted RR = 2.85 (95%CI: 0.91–8.91). 
Among participants with high motivation-to-quit score, 48% of smokers 
included in the reactive phase were abstinent at 1-year follow-up 
compared to 49% of smokers included in the proactive phase (multi-
variable adjusted RR = 1.02, 95%CI: 0.75–1.39). 
At 5-years follow-up, the point estimate was lower, but tended to-
wards the same direction: Among participants with low motivation at 
baseline, 5-year smoking cessation rates were 28% in the reactive phase 
and 55% in the proactive phase (multivariable adjusted RR 2.98, 95%CI: 
0.76–11.7). Smoking cessation rates of highly motivated patients were 
51% in the reactive phase compared to 55% in the proactive phase 
(multivariable adjusted RR 1.07, 95%CI: 0.76–1.51). In sensitivity an-
alyses including participants lost to follow-up as continuous smokers, 
results remained virtually unchanged at 1-year and at 5-years follow-up. 
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4. Discussion 
In this secondary analysis of a before-after trial, we found that self- 
reported motivation-to-quit at baseline modified the effect of a proac-
tive intensive MI-based smoking cessation intervention offered to all 
smokers hospitalized for ACS, regardless of self-reported motivation-to- 
quit. The proportion of smokers with low motivation-to-quit who 
received an intensive smoking cessation intervention increased sub-
stantially, from 14% to 78% between the reactive and proactive phase. 
When smokers received MI-based counseling, the duration of the 
intervention was similar across groups with different motivation to quit 
(45 min vs 50 min), suggesting smokers with low motivation to quit are 
still open to receiving intensive MI smoking cessation counseling. The 
proactive approach of offering MI-based intensive smoking cessation 
intervention was associated with increased smoking cessation at 1 year 
among the smokers with low motivation-to-quit (18% vs 50%), sug-
gesting smokers with low motivation-to-quit appeared to benefit as 
much from the intervention as smokers with high motivation-to-quit. 
These findings challenge current recommendations to offer intensive 
smoking cessation counseling only to hospitalized smokers motivated- 
to-quit. 
Our findings align with studies in the outpatient setting, where 
proactive approaches that delivered telephone-based smoking cessation 
counseling increased smoking cessation rates (Fu et al., 2016; Fu et al., 
2014; Japuntich et al., 2020). Similarly, a RCT among smokers in the 
general population of Denmark showed that smokers at all motivational 
stages who said they had not planned to quit still accepted intensive 
smoking cessation counseling when systematically offered (Pisinger 
et al., 2005b), and this counseling raised smoking cessation rates 
(Pisinger et al., 2005a). 
Our results suggest that proactive counseling benefits inpatient 
smokers after ACS who state they are not motivated to quit. We know of 
only one dedicated RCT that compares the effectiveness of a proactive vs 
reactive approach in the inpatient setting, which just finished recruit-
ment (Faseru et al., 2017). Until then, we have to rely on indirect evi-
dence from previous RCT based on the smokers these studies included. A 
rigorously performed RCT found significant differences in smoking 
cessation rates when testing the benefits of offering MI-based smoking 
cessation intervention to all smokers hospitalized for ACS whether or not 
they were ready to quit (Dornelas et al., 2000). Authors did not present 
stratified analyses based on readiness to quit smoking, so we do not 
know whether those who stated they were not ready to quit benefited as 
Table 1 
Characteristics of participants with information on motivation to quit smoking at baseline.   
All Low motivation High motivation  
Variable  Reactive Phase (N) Proactive phase (N) Reactive Phase (N) Proactive phase (N)  
Total 230 29 18 91 92 p-value 
Age, median years (IQ-range) 55 (49;63) 61 (52; 72) 59 (54; 69) 55 (49; 62) 53 (48;61) 0.014 
Sex, n (%)      0.9 
Female 51 (22) 6 (21) 5 (28) 21 (23) 19 (21) 
Male 179 (78) 23 (79) 13 (72) 70 (77) 72 (79) 
Education*, n (%)      0.10 
University or 65 (28) 7 (24) 5 (28) 22 (24) 31 (33) 
High school; Apprenticeship or lower 162 (71) 21 (72) 13 (72) 69 (76) 59 (64) 
ACS type, n (%)      0.055 
NSTEMI 109 (47) 20 (69) 6 (33) 39 (43) 44 (48)  
STEMI 121 (53) 9 (31) 12 (67) 52 (57) 48 (52)  
Baseline number of cigarettes per day, n (IQ-Range) 20 (10; 24) 20 (6; 30) 20 (10; 24) 20 (10; 20) 20 (10; 24) 0.9 
*3 missings in education. 
Table 2 
Process and clinical outcomes: comparing the effectiveness of proactively and reactively offering an intensive smoking cessation intervention to hospitalized smokers 
after ACS. Results stratified by baseline self-reported motivation to quit smoking before the intervention was offered. Data from one site of the SPUM-ACS study, 
Switzerland*.   


































































































* Participants included in the reactive phase from 08/2009 to 10/2010 and the proactive phase from 11/2010 to 02/2012. 
** Multivariable adjusted generalized linear models following a negative binomial distribution adjusted for sex, age, ACS type (STEMI/NSTEMI), education (University 
grade/High school grade/Apprenticeship or lower) and baseline cigarettes smoked per day. Three participants with missing data on education were excluded from 
multivariable analysis, but sensitivity analysis including them using multiple imputation showed similar results. 
*** Follow-up outcome data for 94% (217/230) of included participants; 8 died within first year, and 5 were lost to follow-up. They were excluded from the analyses 
(see online supplement with flow-chart). 
**** Follow-up outcome data for 68% (156/230) of included participants; 23 died within 5 years, 47 were lost to follow-up and 4 had a missing smoking status. They 
were excluded from analyses (see online supplement with flow-chart). 
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much or more from the intervention than those who stated they were 
ready to quit. In contrast, a subsequent RCT only including smokers 
“willing to make a serious attempt to quit smoking” after ACS, thereby 
excluding smokers with low motivation-to-quit, showed no benefit of 
the smoking cessation intervention (Sivarajan Froelicher et al., 2004). 
These findings highlight the need to consider the motivation to quit of 
included participants in smoking cessation intervention in future 
research. 
Our study has limitations. Since we did not pre-specify stratified 
analyses by motivation-to-quit when we set up our clinical trial, our 
results should be considered exploratory in nature. Our conclusions are 
also limited because we were underpowered to detect meaningful 
changes in these stratified analyses. The multivariable adjusted RR =
2.85 (95%CI: 0.91–8.91) is also consistent with no effect or a negative 
effect of proactive counselling. Also, the before-after design may have 
introduced selection bias over time even though patients hospitalized 
with ACS were consecutively recruited (Auer et al., 2016). Adequately 
powered RCTs needed to further test our hypothesis (Faseru et al., 
2017). The follow-up rate was high at one year. The 5-year analyses 
should be interpreted carefully since we cannot exclude the possibility of 
informative censoring of participants. Furthermore, our data set was 
limited to patients hospitalized at a single site in Switzerland with ACS, 
whose smoking cessation rates are high compared to other health con-
ditions. Future studies should test this hypothesis within a broader range 
of health conditions and settings. 
Our exploratory findings challenge current recommendations to 
allocate high intensity smoking cessation counseling only to those who 
state they are motivated to quit (Fiore et al., 2012). We found that of-
fering MI-based systematic smoking cessation counseling to all smokers 
more effectively reduced smoking rates among smokers hospitalized for 
an ACS overall than restricting delivery of smoking cessation interven-
tion only to smokers motivated to quit. We suggest other researchers 
collect and use data on patients’ motivation to quit smoking when 
testing the effectiveness of MI-based smoking cessation interventions on 
larger and more diverse patient populations. 
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